Your browser doesn't support javascript.
loading
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.
Cheung, Matthew C; Hay, Annette E; Crump, Michael; Imrie, Kevin R; Song, Yuyao; Hassan, Shazia; Risebrough, Nancy; Sussman, Jonathan; Couban, Stephen; MacDonald, David; Kukreti, Vishal; Kouroukis, C Tom; Baetz, Tara; Szwajcer, David; Desjardins, Pierre; Shepherd, Lois; Meyer, Ralph M; Le, Al; Chen, Bingshu E; Mittmann, Nicole.
Afiliação
  • Cheung MC; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Hay AE; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Crump M; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Imrie KR; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Song Y; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Hassan S; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Risebrough N; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Sussman J; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Couban S; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • MacDonald D; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Kukreti V; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Kouroukis CT; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Baetz T; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Szwajcer D; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Desjardins P; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Shepherd L; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Meyer RM; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Le A; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Chen BE; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
  • Mittmann N; Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Canc
J Natl Cancer Inst ; 107(7)2015 Jul.
Article em En | MEDLINE | ID: mdl-25868579
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Custos Hospitalares / Linfoma Tipo de estudo: Health_economic_evaluation Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Custos Hospitalares / Linfoma Tipo de estudo: Health_economic_evaluation Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2015 Tipo de documento: Article